SCHEMBL12430405

SCHEMBL12430405

CC(C)N1C2CC1C2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22951159 0.88
SCHEMBL761441 0.87
SCHEMBL19727316 0.86
SCHEMBL14550719 0.84
SCHEMBL761437 0.82 MAPK1 (0.36)
SCHEMBL22952526 0.82
SCHEMBL14208073 0.80
SCHEMBL18068285 0.80
SCHEMBL18806117 0.80
SCHEMBL19766506 0.80 PIK3CD (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7977328-B2 Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes ASTRAZENECA AB (SE) 2011-07-12 US disclosed
US-7902200-B2 3-[6-(Azetidine-1-carbonyl)pyridin-3-yl]oxy-5-[(3S)-1-methyl-2-oxo-pyrrolidin-3-yl]oxy-N-(5-methylpyrazin-2-yl)benzamide; activates glucokinase leading to decreased glucose threshold for insulin secretion and lowering of blood glucose by increasing hepatic glucose uptake; antidiabetic agents; obesity ASTRAZENECA AB (SE) 2011-03-08 US disclosed
US-20110034432-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATING AGENTS ASTRAZENECA AB (SE) 2011-02-10 US disclosed
US-7842694-B2 Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes ASTRAZENECA AB (SE) 2010-11-30 US disclosed
US-7745475-B2 Such as 3-[(1S)-2-hydroxy-1-methylethoxy]-5-[4-(methylsulfonyl)phenoxy]-N-1,3-thiazol-2-ylbenzamide; glucokinases (Glk) ASTRAZENECA AB (SE) 2010-06-29 US disclosed
US-20100160286-A1 HETEROARYLCARBAMOYLBENZENE DERIVATIVES FOR THE TREATMENT OF DIABETES ASTRAZENECA UK LIMITED AB (SE) 2010-06-24 US disclosed
US-7700640-B2 Process for making phenoxy benzamide compounds ASTRAZENECA AB (SE) 2010-04-20 US disclosed
US-7642259-B2 Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes ASTRAZENECA AB (SE) 2010-01-05 US disclosed
US-7642263-B2 Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes ASTRAZENECA AB (SE) 2010-01-05 US disclosed
US-20090264336-A1 HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES ASTRAZENECA AB (SE) 2009-10-22 US disclosed
US-20090111790-A1 HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES ASTRAZENECA AB (SE) 2009-04-30 US disclosed
US-20090029905-A1 HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES ASTRAZENECA AB (SE) 2009-01-29 US disclosed
US-20080312207-A1 Compounds SYNGENTA CROP PROTECTION AG (CH) 2008-12-18 US disclosed
US-20080280872-A1 Benzamide Derivatives and Their Use as Glucokinase Activating Agents ASTRAZENECA AB (SE) 2008-11-13 US disclosed
US-20080280874-A1 Phenoxy Benzamide Compounds with Utility in the Treatment of Type 2 Diabetes and Obesity ASTRAZENECA AB (SE) 2008-11-13 US disclosed
US-20080234273-A1 Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes ASTRAZENECA AB (SE) 2008-09-25 US disclosed
US-20080200694-A1 Process for Making Phenoxy Benzamide Compounds ASTRAZENECA AB (SE) 2008-08-21 US disclosed
US-20080171734-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2008-07-17 US disclosed
US-20080015203-A1 Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes ASTRAZENECA AB (SE) 2008-01-17 US disclosed
US-20070287693-A1 Benzamide Derivatives That Act Upon The Glucokinase Enzyme ASTRAZENECA AB (SE) 2007-12-13 US disclosed